Remdesivir is developed intend to treat Ebola Virus. It is one of the six known species within the genus Ebolavirus. It is deadly and rare disease in people and non-human primates. This disease was first discovered in 1976 near the Ebola River. Since then, the virus has been infecting people from time to time which leads to outbreaks in several African countries. The virus spread to people initially by a direct contact with body fluids, blood, and tissues of animals. People remain infectious as long as their blood contains the virus. Pregnant women who get acute Ebola and recover from the disease may still carry the virus in breatsmilk or in pregnancy related fluids and tissues. Women who become pregnant after surviving Ebola disease are not at risk of carrying the virus. Symptoms of Ebola Virus includes:
⦁ Sore throat
⦁ Headache
⦁ Muscle pain
⦁ Fatigue
⦁ Fever
Followed by:
⦁ Diarrhea
⦁ Vomiting
⦁ Rash
⦁ Symptoms of impaired kidney and liver function

This drug has the potential at inhibiting the coronavirus. The Coronavirus Disease 2019 (COVID-19) has already spread throughout the world. Coronavirus is a virus that circulate among animals with some of them also known to infect humans. Bats are considered natural hosts of these viruses yet several other species of animals are also known to act as sources. The spread of the virus is person to person and is mainly transmitted through a small respiratory droplets by coughing, sneezing, or people interact with each other. These droplets can be inhaled or can land on surfaces that others may come into contact with or who can then get infected when they touch their mouth, nose, or eyes. Symptoms of the disease may be very mild or more serious such as:
⦁ Cough
⦁ Fever
⦁ Difficulty breathing
Some other symptoms may include:
⦁ Diarrhea
⦁ Fatigue
⦁ Aches and pains
⦁ Headache

Remdesivir was recently tested in a non-human primate model of MERS infection. The drug has inhibited viral replication in lung tissues and prevents formation of lung lesions. Initiation of treatment 12 hours after virus inoculation was similarly effective. The drug has also shown effectiveness against a wide range of coronaviruses. It has already undergone safety testing in clinical trials for Ebola. Thereby, it lessens the time that would be needed for conducting clinical trials for COVID-19.

Nonetheless, there’s still much time of work needed to be done to gain a better understanding of the mechanics of COVID-19. It might be on understanding how the infection acts with the host ACE-2 receptor. Wherein, it is where the infection gains entry into the host. It might reveal how this virus overcame the species barrier between humans and animals. As to what the researchers says that it is critical to identify the intermediate species to stop the current and future spread. The medical authorities around the world are doing their best to have a vaccine for the infectious disease. The best way to be safe at this times is to follow the rules or instructions of your local community/government. [ref: Under Medication]